On April 15, 2021, the U.S. Food and Drug Administration (the “FDA”) notified Five Prime Therapeutics, Inc. that the FDA has approved Five Prime’s request for Breakthrough Therapy Designation for bemarituzumab as first-line treatment of patients with fibroblast growth factor receptor 2b (FGFR2b) overexpressing and human epidermal growth factor receptor 2 (HER2)-negative metastatic and locally advanced gastric and gastroesophageal adenocarcinoma in combination with fluoropyrimidine, leucovorin, and oxaliplatin based on an FDA-approved companion diagnostic assay showing at least 10% of tumor cells overexpressing FGFR2b.